Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-19
2005-07-19
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S282100, C546S282700, C549S398000, C549S404000, C514S337000, C514S456000
Reexamination Certificate
active
06919371
ABSTRACT:
This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
REFERENCES:
patent: 3706764 (1972-12-01), Nakanishi et al.
patent: 3803176 (1974-04-01), Christensen et al.
patent: 4647579 (1987-03-01), Kabbe et al.
patent: 4650812 (1987-03-01), Cohen et al.
patent: 4654362 (1987-03-01), Van Lommen et al.
patent: 5393775 (1995-02-01), Le Baut et al.
patent: 5451677 (1995-09-01), Fisher et al.
patent: 5516917 (1996-05-01), Djuric et al.
patent: 5541197 (1996-07-01), Fisher et al.
patent: 5561142 (1996-10-01), Fisher et al.
patent: 5663194 (1997-09-01), Newshaw
patent: 5977154 (1999-11-01), Bell et al.
patent: 6051586 (2000-04-01), Ladouceur et al.
patent: 6469031 (2002-10-01), Connell et al.
patent: 2511647 (1975-09-01), None
patent: 0079637 (1983-05-01), None
patent: 0091749 (1983-10-01), None
patent: 0328251 (1989-08-01), None
patent: 0611003 (1994-08-01), None
patent: 0801060 (1997-10-01), None
patent: 2746395 (1997-09-01), None
patent: 8198866 (1996-08-01), None
patent: 08198866 (1996-08-01), None
patent: 9429290 (1994-12-01), None
patent: 9525104 (1995-09-01), None
patent: 9529159 (1995-11-01), None
patent: 9735835 (1997-10-01), None
patent: 9746556 (1997-12-01), None
patent: 9832753 (1998-07-01), None
patent: 9965877 (1999-12-01), None
CAPLUS AN: 2004:615587, Iatropoulos et al, abstract of “The function and pathology of brown adipose tissue in animals and humans,” Journal of Toxicologic Pathology (2004), vol. 17 (2), pp. 147-153.
CAPLUS AN: 2001:699585, Cederberg et al, “FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance,” Cell (2001), vol. 106 (5), pp. 563-573.
CAPLUS AN: 200122029, Manraj et al, “Genetic & environmental nature of the insulin resistance syndrome in Indo-Mauritian subjects with premature coronary heart disease: contribution of beta-3 adrenoreceptor gene . . . ”, Diabetologia (2001), vol. 44 (1) pp. 115.
CAPLUS AN: 2000:165957, Proenza et al,m “Association of sets of alleles of genes encoding beta-3 adrenorecepto . . . ”, International Journal of Obesity (2000), vol. 24 (1), pp. 93-100.
Hu, B., Ellingboe, J., Gunawan, I., Han, S., Largis, E., Li, Z., Malamas, M., Mulvey, R., Oliphant, A., Sum, F.-W., Tillett, J., Wong, V., “2,4-Thiazolidinediones as Potent and Selective Human ∃3 Agonists”, Bioorganic & Medicinal Chemistry Letters, 11: 757-760 (2001).
Murata, M., Watanabe, S., and Masuda, Y., “Novel Palladium(0)-Catalyzed Coupling Reaction of Dialkozyborane with Aryl Halides: Convenient Synthetic Route to Arylboronates”, J. Org., Chem., 62: 6458-6459 (1997).
Bullock William H.
Campbell Ann-Marie
Dai Miao
Dally Robert
Dumas Jacques
Bayer Pharmaceuticals Corporation
Coppins Janet L.
McKane Joseph K.
Pellegrino Susan M.
LandOfFree
2,6-substituted chroman derivatives useful as beta-3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,6-substituted chroman derivatives useful as beta-3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,6-substituted chroman derivatives useful as beta-3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3384089